Company intelligence / Profile preview
Chong Kun Dang Pharmaceutical
Seoul, Seoul, South Koreackdpharm.com ↗
- Ownership
- Public · 185750
- Employees
- ~2400
- Development stage
- Commercial
01
Overview
Chong Kun Dang has a robust clinical pipeline with several commercialized drugs in Korea and Asia. Notable achievements include the first Korean FDA approval for export to the US market. Recent highlights include a $1.3 billion technology transfer deal with Novartis for an HDAC6 inhibitor program and ongoing development of innovative therapies in oncology and metabolic diseases. The company invests heavily in R&D (~150 billion KRW/year) to expand its global presence
- Therapeutic areas
- CardiovascularEndocrinologyHematologyOncologyRare Diseases
- Modalities
- Small moleculesbiologicsbiosimilarsbispecific antibodies
- Industry
- Biotech
02
Drug pipeline
87 assets86 more assets in the full pipeline.
Request access →03
Partnerships
Novartis (HDAC6 program)GC Biopharma (Neulapeg co-marketing)Healis Therapeutics (neuromodulator protein development)Aclipse Therapeutics (lobeglitazone licensing)
Beyond the preview
Go deeper on Chong Kun Dang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chong Kun Dang Pharmaceutical.